CJC-1295 + Ipamorelin: Growth Hormone Peptide Research Guide
CJC-1295 and Ipamorelin are two growth-hormone-axis research peptides that are frequently studied together because they act through distinct, complementary receptor systems that converge on the same pituitary target cell. CJC-1295 is characterized in the literature as a synthetic analog of growth-hormone-releasing hormone (GHRH), engineered to activate the GHRH receptor on pituitary somatotrophs, while Ipamorelin is described as a highly selective growth-hormone secretagogue that activates the ghrelin receptor (GHS-R1a) through a separate signaling pathway. This CJC-1295 Ipamorelin research guide is written for laboratory investigators who want a single, technically grounded reference covering classification, dual-pathway mechanism, structural chemistry, analytical verification, and proper handling for in-vitro and preclinical research — with no dosing instructions, therapeutic claims, or human-use guidance provided or implied anywhere in this guide.
What Are CJC-1295 and Ipamorelin? Classification and Molecular Identity
Before any mechanistic or experimental discussion is useful, it helps to place each peptide correctly within the broader taxonomy of growth-hormone (GH) axis research compounds. CJC-1295 and Ipamorelin are not variants of the same molecule, and they are not interchangeable — they belong to two structurally and pharmacologically distinct classes of GH-axis secretagogue that happen to be studied together because of how their mechanisms complement one another.
CJC-1295: A GHRH Receptor Agonist
CJC-1295 is classified as a synthetic analog of growth-hormone-releasing hormone (GHRH), built on the same 29-amino-acid backbone segment — GHRH(1-29) — that underlies other GHRH-class research peptides. Specific amino acid substitutions are introduced at positions known to be vulnerable to enzymatic cleavage, most notably by dipeptidyl peptidase-4 (DPP-4), which is reported in the literature to rapidly degrade native GHRH and unmodified GHRH(1-29) fragments in biological systems. Some formulations of CJC-1295 additionally incorporate a Drug Affinity Complex (DAC), a chemical modification designed to promote covalent binding to circulating serum albumin — a distinction covered in detail later in this guide.
Ipamorelin: A Selective GH Secretagogue
Ipamorelin belongs to an entirely different structural class: it is a pentapeptide — a five-amino-acid chain — classified as a growth hormone-releasing peptide (GHRP), or more precisely as a ghrelin-mimetic growth hormone secretagogue. Unlike CJC-1295, Ipamorelin does not act on the GHRH receptor at all. Instead, it is characterized in pharmacological research as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor that the endogenous hormone ghrelin activates. Ipamorelin is frequently distinguished from earlier GHRP-class compounds by a comparatively narrow selectivity profile, discussed further in the comparison section below.
Why the Two Are Discussed as a Pair
Research teams organizing a GH-axis pipeline typically encounter CJC-1295 and Ipamorelin listed together — including in Royal Peptide Labs’ own CJC-1295 + Ipamorelin 10mg research peptide listing — not because they are chemically related, but because they are frequently combined in experimental protocols investigating GH pulsatility. That rationale is explored fully in the mechanism sections that follow. Both compounds fall within Royal Peptide Labs’ broader growth hormone peptides research category, alongside other GHRH- and GHRP-class compounds used in comparative pharmacology work.
The table below summarizes the identity parameters a research team typically needs before designing a GH-axis protocol involving either or both compounds.
| Parameter | CJC-1295 | Ipamorelin |
|---|---|---|
| Compound class | Synthetic GHRH analog (GHRH receptor agonist) | Selective GH secretagogue (GHS-R1a / ghrelin receptor agonist) |
| Backbone origin | Modified GHRH(1-29) sequence | Pentapeptide (5 amino acids), not GHRH-derived |
| Primary receptor target | Growth hormone-releasing hormone receptor (GHRHR) | Growth hormone secretagogue receptor (GHS-R1a) |
| Receptor class | Class B GPCR | Class A GPCR |
| Notable modification | DPP-4-resistance substitutions; optional DAC conjugation | Structured for receptor selectivity relative to earlier GHRPs |
| Supplied form | Lyophilized (freeze-dried) powder, research-use-only | Lyophilized (freeze-dried) powder, research-use-only |
| Common literature category | GHRH-class GH-axis research peptide | GHRP-class / ghrelin-mimetic GH-axis research peptide |
That receptor-class distinction — GHRH receptor versus GHS-R1a — is the single most important fact to hold onto throughout this guide, because it is the reason these two peptides are studied together rather than as substitutes for one another.
The Growth Hormone Axis: Where GHRH and GHRP Pathways Converge
To understand why CJC-1295 and Ipamorelin research is so often designed around the two compounds jointly, it is necessary to understand the basic architecture of the hypothalamic-pituitary GH axis that both are studied within.
The Hypothalamic-Pituitary-Somatotroph Circuit
Growth hormone (GH) is synthesized and released from somatotroph cells in the anterior pituitary gland. That release is governed by a balance of stimulatory and inhibitory signals originating in the hypothalamus. The principal stimulatory signal is GHRH, released from hypothalamic neurons and acting on the GHRH receptor expressed on somatotrophs. The principal inhibitory signal is somatostatin, which suppresses GH release through a separate receptor system. Layered on top of this classic GHRH/somatostatin axis is a third input: ghrelin, a peptide hormone (produced primarily in the stomach, though also synthesized centrally) that acts on GHS-R1a, expressed both in the hypothalamus and directly on pituitary somatotrophs, to further stimulate GH release and, in some research models, to blunt somatostatin’s inhibitory tone.
Two Distinct Molecular “Inputs” to the Same Output
This three-signal architecture is precisely what makes CJC-1295 and Ipamorelin research mechanistically interesting as a pair. CJC-1295, as a GHRH receptor agonist, is studied as a stand-in for the GHRH input to this circuit. Ipamorelin, as a GHS-R1a agonist, is studied as a stand-in for the ghrelin input. Because GHRH and ghrelin are reported in the literature to act on somatotrophs through distinct intracellular signaling cascades — GHRH receptor activation is classically linked to G-protein/adenylate cyclase/cAMP signaling, while GHS-R1a activation is classically linked to Gq/phospholipase-C/inositol-triphosphate/calcium signaling — a combined CJC-1295 and Ipamorelin protocol allows researchers to probe both signaling arms of the GH-release circuit within the same experimental system, rather than being limited to a single input pathway.
Downstream: The GH–IGF-1 Feedback Loop
GH released from the pituitary acts on peripheral tissues, most notably the liver, to stimulate synthesis of insulin-like growth factor 1 (IGF-1). IGF-1, in turn, participates in a negative-feedback loop, acting on both the hypothalamus and pituitary to modulate further GH release. Research protocols examining CJC-1295 and Ipamorelin frequently extend beyond the immediate GH-release readout to examine downstream IGF-1 signaling, making the GH-IGF-1 axis a natural organizing framework for interpreting data generated with either or both compounds.
Pathway Convergence Diagram in Table Form
| Signal | Receptor | Primary Intracellular Pathway | Research Compound Studied as a Model |
|---|---|---|---|
| GHRH | GHRH receptor (GHRHR) | Gs / adenylate cyclase / cAMP | CJC-1295 (and other GHRH-class analogs) |
| Ghrelin | GHS-R1a | Gq / phospholipase-C / IP3 / calcium | Ipamorelin (and other GHRP-class secretagogues) |
| Somatostatin | Somatostatin receptors (SSTR subtypes) | Gi / inhibition of adenylate cyclase | Not directly targeted by either compound; relevant as a background inhibitory tone |
Understanding this three-way architecture is the conceptual foundation for nearly every experimental design question addressed later in this guide, from model selection to comparative pharmacology.
Species Differences and Translational Considerations
Researchers moving between cell-based, ex-vivo, and animal-model systems should be attentive to species differences in GHRH receptor and GHS-R1a expression, sequence homology, and downstream signaling machinery. Rodent models remain the most common systemic model for GH-axis secretagogue research, but receptor sequence and expression-pattern differences between rodent and human systems mean that findings generated in one model tier should not be assumed to translate directly to another without independent confirmation. This is a standard caveat across GPCR pharmacology generally, but it carries particular weight for GH-axis research given how tightly regulated and species-variable the hypothalamic-pituitary circuit is reported to be. A well-designed comparative protocol will typically specify, and where possible directly test, the species or cell-line origin of the receptor system under study rather than assuming uniformity across model tiers.
CJC-1295 Ipamorelin Research: The Combined GH-Axis Model
Because CJC-1295 and Ipamorelin engage the GH axis through separate receptor systems, combining them in a single research protocol is one of the more common experimental design choices in GH-secretagogue pharmacology. This section addresses the rationale directly, and the methodological considerations that follow from it.
The Convergence Hypothesis
The central hypothesis underlying most combined CJC-1295 Ipamorelin research is that concurrent engagement of the GHRH receptor and GHS-R1a on the same somatotroph population produces a GH-release signaling profile distinct from either input alone. Because the two receptors couple to different primary G-protein pathways (Gs/cAMP for GHRHR, Gq/calcium for GHS-R1a), researchers are able to investigate whether these two signaling cascades interact additively, synergistically, or through some more complex cross-talk mechanism at the level of the somatotroph cell — a question that cannot be answered by studying either compound in isolation.
Somatostatin Tone as a Third Variable
A recurring theme in the literature on combined GHRH/GHRP research is the role of somatostatin as a modulating background variable. Ghrelin-receptor agonism (the GHS-R1a pathway that Ipamorelin models) has been reported to interact with somatostatin signaling in ways that differ from GHRH-receptor agonism, meaning that a combined-compound protocol is often specifically designed to probe whether the two agonists interact with inhibitory somatostatin tone differently when studied together versus separately. Well-designed protocols typically include a somatostatin-pathway control arm, or use model systems where somatostatin tone can be experimentally manipulated, to isolate this variable.
Experimental Design Patterns for Combined-Compound Studies
- Sequential single-agonist controls — testing CJC-1295 alone and Ipamorelin alone within the same experimental run as the combined condition, so that any combined-condition signaling behavior can be properly benchmarked against each single-pathway input.
- Time-course design — because GHRH-receptor and GHS-R1a signaling kinetics may differ, protocols often stagger exposure timing or use parallel time-course sampling to characterize each pathway’s contribution across the full response window rather than at a single endpoint.
- Dose-response matrices — in cell-based systems, a matrix design testing multiple concentrations of each compound alone and in combination allows researchers to formally test for additive versus synergistic interaction using standard pharmacological interaction models.
- Downstream readouts beyond acute GH release — combined-compound protocols frequently extend to IGF-1 production, somatotroph proliferation markers, or receptor expression changes following repeated exposure, depending on the research question.
What “Synergy” Means Methodologically — and What It Does Not Claim
It is worth being precise here: characterizing two agonists as producing a synergistic or additive signaling profile in a specific assay is a statement about that assay’s readout under those specific conditions — not a general outcome claim, and not a statement about any effect in a whole organism outside a defined research model. This guide does not report or imply specific quantitative findings from any study; it describes why the combined-compound research design exists and how it is typically structured. Researchers interested in primary findings should consult the searchable literature referenced at the end of this guide.
Because GHRH-class and GHRP-class compounds are mechanistically distinct rather than redundant, researchers frequently benefit from reviewing a dedicated explainer on how the two receptor classes differ before finalizing a combined-compound protocol — see GHRH vs. GHRP: growth hormone peptides explained for that grounding, and the head-to-head CJC-1295 vs. Ipamorelin comparison for a more granular side-by-side treatment of the two compounds specifically.
CJC-1295 Structure, Chemistry & GHRH Receptor Mechanism
CJC-1295’s research relevance follows directly from its chemistry, which was specifically engineered to address a well-documented limitation of native GHRH and earlier GHRH(1-29) fragments studied in the laboratory.
Backbone and Stabilizing Substitutions
Native GHRH and its truncated GHRH(1-29) research analog are reported in the literature to be rapidly cleaved by dipeptidyl peptidase-4 (DPP-4), an enzyme that clips the peptide near its N-terminus and substantially shortens its functional presence in biological systems. CJC-1295 addresses this by introducing targeted amino acid substitutions at the DPP-4-vulnerable positions, along with additional substitutions reported to improve overall resistance to enzymatic and chemical degradation (such as oxidation-prone residues). The result is a GHRH-receptor agonist peptide that retains the receptor-binding architecture of the native GHRH(1-29) sequence while being substantially more stable against the enzymatic degradation pathways that limit unmodified GHRH fragments in research systems.
GHRH Receptor Engagement
Functionally, CJC-1295 is studied as an agonist at the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on pituitary somatotrophs. Receptor engagement is classically linked to activation of adenylate cyclase and a resulting rise in intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA) signaling — the canonical pathway associated with GH synthesis and secretion from somatotroph cells in cell-based and ex-vivo pituitary research models.
The DAC Modification (Where Present)
Some CJC-1295 preparations additionally incorporate a Drug Affinity Complex (DAC) — a chemical modification (typically a maleimide-based reactive group) engineered to form a covalent bond with a cysteine residue on circulating serum albumin once introduced into a biological system. This is a distinct design layer from the DPP-4-resistance substitutions described above, and it is the specific feature that differentiates “CJC-1295 with DAC” from “CJC-1295 without DAC,” a distinction detailed in its own section below.
Structural Snapshot
| Structural Feature | Description |
|---|---|
| Base sequence | Modified GHRH(1-29) backbone |
| Key modification purpose | Resistance to DPP-4 enzymatic cleavage |
| Optional secondary modification | Drug Affinity Complex (DAC) for covalent albumin binding |
| Receptor engaged | GHRH receptor (GHRHR), class B GPCR |
| Primary intracellular pathway | Gs / adenylate cyclase / cAMP / PKA |
| Physical form supplied | Lyophilized powder, research-use-only |
Why the Chemistry Matters for Study Design
Because DPP-4 expression and activity can vary between cell lines, tissue preparations, and animal models, researchers designing GHRH-pathway protocols with CJC-1295 should be attentive to the DPP-4 expression profile of their chosen model system — a model with high endogenous DPP-4 activity may behave differently toward CJC-1295 than a model with low DPP-4 expression, even though CJC-1295 is specifically engineered for greater DPP-4 resistance relative to unmodified GHRH(1-29). This is a methodological detail worth confirming before drawing comparative conclusions across different model systems.
Ipamorelin Structure, Chemistry & Selective GHS-R1a Mechanism
Ipamorelin’s defining research characteristic is its receptor selectivity, and understanding why requires looking at both its minimal structure and the receptor pharmacology it was designed around.
A Minimal Pentapeptide Structure
Ipamorelin is a pentapeptide — five amino acids in length — which places it among the smallest peptides commonly studied in GH-axis research, considerably shorter than the 29-30 residue GHRH-class analogs like CJC-1295. This compact structure is characterized in the pharmacological literature as contributing to a more selective receptor-binding profile relative to earlier, larger GHRP-class compounds, a topic explored further in the comparison section below.
GHS-R1a Agonism
Ipamorelin is studied as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), a class A G-protein-coupled receptor that is also the endogenous target of ghrelin. GHS-R1a is expressed on pituitary somatotrophs directly, as well as in hypothalamic neurons involved in GH-axis regulation. Receptor activation is classically associated with Gq-protein coupling, leading to phospholipase-C activation, inositol trisphosphate (IP3) generation, and a resulting rise in intracellular calcium — a signaling cascade mechanistically distinct from the cAMP/PKA pathway associated with GHRH receptor activation by compounds like CJC-1295.
Selectivity Relative to Other Receptor Systems
A key research distinction reported for Ipamorelin, relative to earlier GHRP-class secretagogues, is comparatively limited cross-reactivity at receptor systems associated with cortisol, adrenocorticotropic hormone (ACTH), and prolactin secretion. Earlier GHRPs — discussed in the comparison table later in this guide — are reported in the literature to produce more pronounced activity at these secondary pathways alongside their GH-secretagogue activity. This selectivity profile is precisely why Ipamorelin is frequently the GHRP-class compound of choice in research designs specifically aiming to isolate GHS-R1a-mediated GH-axis signaling from these adjacent hormonal pathways.
Structural and Mechanistic Snapshot
| Structural Feature | Description |
|---|---|
| Chain length | Pentapeptide (5 amino acids) |
| Structural class | Synthetic GHRP / ghrelin-mimetic secretagogue |
| Receptor engaged | GHS-R1a (growth hormone secretagogue receptor), class A GPCR |
| Primary intracellular pathway | Gq / phospholipase-C / IP3 / calcium |
| Notable selectivity feature | Comparatively limited cross-reactivity at cortisol/ACTH/prolactin-linked pathways relative to earlier GHRPs |
| Physical form supplied | Lyophilized powder, research-use-only |
Why Selectivity Is a Research Design Advantage
In an experimental system where the research question is specifically about GH-axis signaling — rather than the broader constellation of pituitary hormone pathways — a more selective ligand reduces the number of confounding variables that must be controlled for or interpreted around. This is a major reason Ipamorelin is so frequently paired with CJC-1295 in combined-compound protocols: researchers can attribute the GHS-R1a-attributable component of an observed signaling response with greater confidence than they could using a less selective GHRP-class comparator, because Ipamorelin’s off-target activity at adjacent pituitary hormone pathways is reported to be minimal relative to earlier compounds in its structural class.
CJC-1295 With DAC vs. Without DAC (Mod GRF 1-29): Research Distinctions
One of the most common points of confusion in GHRH-analog research is the distinction between “CJC-1295 with DAC” and “CJC-1295 without DAC” — sometimes labeled Mod GRF 1-29 in supplier catalogs and research literature. These are related but functionally distinct research tools, and conflating them in a protocol or a comparative literature review is a common — and avoidable — methodological error.
What DAC Adds, Chemically
As described in the structure section above, the Drug Affinity Complex (DAC) is a chemical modification appended to the base CJC-1295 peptide sequence, engineered to form a covalent bond with circulating serum albumin. “CJC-1295 without DAC” — the form generally referred to as Mod GRF 1-29 — carries the same core DPP-4-resistance substitutions but lacks this albumin-binding conjugate.
Functional Consequence: Duration of Receptor Engagement
The presence or absence of the DAC conjugate is reported in the literature to meaningfully affect how long the compound remains functionally available for GHRH receptor engagement within a biological system, because covalent albumin binding is understood to substantially slow renal clearance relative to the unconjugated form. Researchers should treat this as a qualitative, mechanism-level distinction — the DAC-conjugated form is characterized as producing a substantially extended functional presence relative to the non-DAC form — rather than relying on any specific numerical half-life figure, since precise pharmacokinetic values vary by model system, administration route, and assay methodology, and are best sourced directly from primary literature rather than from a general reference guide.
Implications for Experimental Design
| Design Consideration | CJC-1295 without DAC (Mod GRF 1-29) | CJC-1295 with DAC |
|---|---|---|
| Typical research use case | Acute, short-window signaling assays; pulsatile-exposure protocols | Extended-exposure or sustained receptor-engagement protocols |
| Albumin-binding conjugate | Absent | Present (covalent, via maleimide-type linker) |
| Relative functional duration in biological systems | Shorter, consistent with unconjugated GHRH-class peptides | Extended, consistent with albumin-binding conjugate chemistry |
| Common comparative role in the literature | Benchmark for “native-like” GHRH-receptor kinetics | Benchmark for long-acting GHRH-receptor engagement strategies |
Why This Distinction Matters for Reproducibility
Because these two forms are pharmacologically related but functionally distinct, any research write-up, protocol, or literature comparison that refers simply to “CJC-1295” without specifying whether the DAC-conjugated or non-DAC form was used introduces meaningful ambiguity. Researchers replicating or comparing across studies should confirm which form was used in any reference study before drawing conclusions about apparent discrepancies in observed signaling duration or magnitude — a discrepancy attributable to DAC status is not the same as a discrepancy attributable to genuine biological variability.
Sourcing Clarity
Because this distinction is so consequential for experimental design, product listings and certificates of analysis should clearly specify which form of CJC-1295 is being supplied. Researchers should confirm this detail directly against the documentation associated with the specific CJC-1295 + Ipamorelin product listing they are sourcing from, rather than assuming a default, since supplier conventions are not fully standardized across the research-peptide industry.
Research Applications and Laboratory Model Systems
CJC-1295 and Ipamorelin, individually and in combination, are studied across a range of model systems suited to different tiers of GH-axis research questions. This section surveys those model classes without describing or implying any specific study outcome.
In-Vitro Pituitary Cell Culture Systems
Cultured pituitary cell lines, including somatotroph-enriched preparations, are a foundational model for isolating direct receptor-level signaling in response to CJC-1295, Ipamorelin, or both. These systems allow researchers to measure cAMP accumulation (associated with GHRH receptor activation), calcium flux (associated with GHS-R1a activation), and GH release into culture media under tightly controlled conditions, without the confounding influence of the intact hypothalamic-pituitary circuit.
Ex-Vivo Pituitary Explant Models
Ex-vivo pituitary tissue explants preserve more of the native cellular architecture and paracrine signaling environment than dissociated cell culture, allowing researchers to study CJC-1295 and Ipamorelin’s effects in a system where somatotrophs remain in their native tissue context alongside other pituitary cell types. This model tier is often used as a bridge between simplified cell-culture assays and more complex whole-animal studies.
Hypothalamic-Pituitary Co-Culture and Explant Systems
Because ghrelin-receptor signaling (modeled by Ipamorelin) is understood to act at both the hypothalamic and pituitary level, some research designs specifically incorporate hypothalamic tissue or co-culture systems alongside pituitary preparations, to capture GHS-R1a-mediated modulation of hypothalamic somatostatin or GHRH-neuron activity — an additional layer of complexity not captured in pituitary-only systems.
Animal Model Research
Rodent and other animal models remain the standard system for investigating systemic GH-axis questions, including pulsatile GH-release patterns, downstream IGF-1 production, and feedback-loop dynamics that cannot be fully captured in isolated cell or tissue systems. As with all sections of this guide, no outcome data from any animal study is described or implied here; researchers should consult primary, peer-reviewed sources for outcome-level information.
Common Research Question Categories by Model Tier
| Model Tier | Typical Use | Key Advantage |
|---|---|---|
| Dissociated pituitary cell culture | Isolated receptor-signaling assays (cAMP, calcium, GH release) | High experimental control, minimal confounding |
| Ex-vivo pituitary explants | Signaling in preserved native tissue architecture | Retains paracrine cell-cell signaling context |
| Hypothalamic-pituitary co-culture | Capturing GHS-R1a effects at both regulatory levels | Models somatostatin/GHRH-neuron interaction |
| Animal models | Systemic GH pulsatility and IGF-1 feedback research | Captures whole-circuit, multi-organ dynamics |
Selecting the appropriate model tier depends heavily on whether the underlying research question is receptor-mechanistic (favoring simpler, well-controlled systems) or systems-level (favoring explant or animal models) — a distinction worth settling before compound sourcing and protocol design begin.
Receptor Expression Validation Before Study Initiation
Regardless of which model tier a research team selects, confirming that the chosen cell line, tissue preparation, or animal strain actually expresses the receptor of interest — GHRHR for CJC-1295 work, GHS-R1a for Ipamorelin work, or both for combined-compound protocols — is a foundational step that is sometimes skipped in favor of relying on prior literature characterizations of a given model system. Receptor expression can drift with passage number in immortalized cell lines, and can vary by supplier or breeding line in animal models. A brief receptor-expression confirmation step, whether by quantitative PCR, western blot, or a simple positive-control ligand response, is inexpensive relative to the cost of running a full experimental protocol on a model system that turns out to express the target receptor at unexpectedly low levels.
Comparing CJC-1295 + Ipamorelin to Other GH-Axis Secretagogues
CJC-1295 and Ipamorelin do not exist in isolation within the GH-axis research literature — they sit alongside a family of related GHRH-class and GHRP-class compounds, each with distinct selectivity and structural profiles. Understanding where they fall on this spectrum is essential for designing defensible comparative protocols.
GHRH-Class Comparators
Within the GHRH-analog class, CJC-1295 is most frequently compared against Sermorelin (essentially unmodified GHRH(1-29), lacking CJC-1295’s stabilizing substitutions) and Tesamorelin (a GHRH analog carrying a distinct N-terminal modification). These three compounds share the same GHRH-receptor target but differ meaningfully in structural modification strategy and, by extension, in their reported stability and functional duration in research systems. A dedicated side-by-side treatment of CJC-1295 relative to Sermorelin is available for researchers designing GHRH-class comparative protocols, and Royal Peptide Labs’ own Tesamorelin research guide provides a full mechanistic treatment of that specific comparator compound.
GHRP-Class Comparators
Within the GHRP/ghrelin-mimetic class, Ipamorelin is most frequently compared against GHRP-6, GHRP-2, and Hexarelin — earlier-generation secretagogues that share the GHS-R1a target but are reported to differ substantially in receptor selectivity. GHRP-6 in particular is associated in the literature with more pronounced activity at pathways linked to appetite signaling, cortisol, and prolactin release, alongside its GHS-R1a activity. Hexarelin is reported as among the most potent GHS-R1a agonists in this class, but also among the least selective, with cross-reactivity noted at cardiac tissue receptor systems in some research characterizations.
Full Comparative Table
| Compound | Class | Receptor Target | Reported Selectivity Profile |
|---|---|---|---|
| CJC-1295 | GHRH analog | GHRH receptor | Engineered for DPP-4 resistance; optional DAC for extended albumin binding |
| Sermorelin | GHRH analog | GHRH receptor | Closer to native GHRH(1-29); shorter functional presence reported |
| Tesamorelin | GHRH analog | GHRH receptor | Distinct N-terminal modification strategy from CJC-1295 |
| Ipamorelin | GHRP / ghrelin mimetic | GHS-R1a | Comparatively selective; limited cortisol/ACTH/prolactin cross-reactivity reported |
| GHRP-6 | GHRP / ghrelin mimetic | GHS-R1a | Less selective; notable appetite-pathway and cortisol/prolactin activity reported |
| GHRP-2 | GHRP / ghrelin mimetic | GHS-R1a | Intermediate selectivity relative to GHRP-6 and Ipamorelin |
| Hexarelin | GHRP / ghrelin mimetic | GHS-R1a | High reported potency; least selective, with cardiac-tissue cross-reactivity noted |
Why CJC-1295 + Ipamorelin Is a Common Reference Pairing
Given this landscape, CJC-1295 paired with Ipamorelin represents a combination researchers often select specifically because each half of the pairing is characterized as relatively “clean” within its own structural class — CJC-1295 for its engineered stability advantage over native GHRH fragments, and Ipamorelin for its selectivity advantage over earlier GHRPs. This makes the pairing a useful reference-standard combination for isolating genuine dual-pathway (GHRH-receptor plus GHS-R1a) signaling behavior, with fewer off-target confounds than combinations involving less selective comparator compounds. For a deeper single-compound comparison specifically, see CJC-1295 vs. Ipamorelin: how they differ in research.
Receptor Selectivity and Signaling Specificity
Because CJC-1295 and Ipamorelin are so often studied together, a rigorous research program needs a clear-eyed view of exactly how selective each compound actually is — and what “selective” means at the level of receptor pharmacology rather than as a loosely applied descriptor.
Defining Selectivity in GH-Axis Research
A compound’s selectivity refers to how narrowly it engages its intended target receptor relative to structurally or functionally related receptor systems. For CJC-1295, that means characterizing its activity at the GHRH receptor relative to other class B GPCRs in the same broader receptor family. For Ipamorelin, it means characterizing GHS-R1a engagement relative to receptor systems linked to cortisol, ACTH, and prolactin secretion, since these are the off-target pathways most commonly associated with less selective GHRP-class comparators.
Assessing CJC-1295’s Receptor Specificity
Because CJC-1295 is built on the native GHRH(1-29) backbone with targeted stabilizing substitutions rather than a wholesale re-engineering of the receptor-binding domain, it is generally characterized as retaining the receptor-binding specificity profile of native GHRH — meaning its primary research value lies in extended functional stability rather than in an altered selectivity profile relative to unmodified GHRH fragments. Confirming this in a specific model system (via receptor-binding or functional assays against a GHRH receptor-expressing line) remains good practice rather than an assumption to be taken for granted.
Assessing Ipamorelin’s Receptor Specificity
Ipamorelin’s selectivity claim is more central to its research identity, since it is specifically the feature that differentiates it from earlier GHRP-class compounds. Research protocols aiming to characterize or confirm this selectivity typically include counter-screening against receptor systems associated with cortisol, ACTH, and prolactin release, alongside the primary GHS-R1a binding and functional assay. This is standard due diligence for any laboratory establishing a new compound source, not a step that should be skipped based on labeling claims alone.
Signaling Bias Considerations
Beyond raw receptor selectivity, both GHRHR and GHS-R1a — like most GPCRs — are capable of coupling to more than one downstream signaling pathway, and a ligand’s relative bias toward one pathway over another (canonical G-protein signaling versus beta-arrestin-mediated pathways, for example) is itself an active area of receptor pharmacology research. Characterizing whether CJC-1295 and Ipamorelin exhibit signaling bias at their respective receptors, and whether that bias differs from native GHRH and ghrelin, is a more advanced research question layered on top of the basic selectivity characterization described above.
Selectivity Research Summary
| Research Question | Typical Assay Approach |
|---|---|
| CJC-1295 binding specificity at GHRHR vs. related receptors | Radioligand or fluorescence competition binding assay |
| Ipamorelin selectivity for GHS-R1a vs. cortisol/ACTH/prolactin pathways | Counter-screening panel across relevant receptor systems |
| Signaling bias at GHRHR or GHS-R1a | Parallel cAMP (GHRHR) and calcium/IP3 (GHS-R1a) assays, with beta-arrestin recruitment panels where feasible |
| Cross-pathway interaction in combined-compound protocols | Dose-response matrix design with single- and combined-agonist arms |
Analytical Purity: HPLC, Mass Spectrometry, and COA Interpretation
For both CJC-1295 and Ipamorelin, analytical verification of identity and purity is a prerequisite for interpretable research data, not an optional add-on. Because the two compounds differ substantially in size and structure — a 29-30 residue GHRH analog versus a five-residue pentapeptide — they also differ somewhat in the specific purity considerations that matter most.
High-Performance Liquid Chromatography (HPLC)
Reverse-phase HPLC (RP-HPLC) remains the standard method for quantifying purity in both compounds, separating the intended full-length peptide from truncated fragments, deletion sequences, and other synthesis-related impurities that can arise during solid-phase peptide synthesis. Because CJC-1295 is a substantially longer chain than Ipamorelin, it carries a proportionally greater risk of incomplete coupling or deletion-sequence impurities during synthesis, making a clean, dominant HPLC peak — with minimal shouldering or secondary peaks — an especially important signal to confirm before use. Ipamorelin’s short pentapeptide structure is comparatively less synthesis-error-prone, but purity verification remains essential rather than optional.
Mass Spectrometry (MS)
Mass spectrometry complements HPLC by confirming molecular identity — verifying that the dominant chromatographic peak actually corresponds to the expected molecular weight of CJC-1295 or Ipamorelin, respectively, rather than to a co-eluting synthesis byproduct or an entirely different compound. Electrospray ionization mass spectrometry (ESI-MS) is commonly used for peptides across this size range, and a properly documented certificate of analysis will report an observed mass consistent with each compound’s expected molecular identity.
Reading a Certificate of Analysis for a Combination Product
Because CJC-1295 and Ipamorelin are frequently supplied together as a combination research product, a complete certificate of analysis should document both compounds independently, not as a single undifferentiated purity figure. At minimum, a rigorous COA should include:
- Lot or batch identifier — specific to the combination product received, allowing full traceability.
- Separate HPLC purity results for CJC-1295 and for Ipamorelin — since a blended purity figure can obscure a problem isolated to one of the two compounds.
- Separate mass spectrometry identity confirmation for each compound — confirming both molecular identities independently.
- Ratio or quantity documentation — clarity on the relative amount of each compound present, where the product is supplied as a blend.
- Testing date and testing laboratory — in-house or third-party, so researchers can weight the documentation appropriately.
Royal Peptide Labs publishes lot-specific documentation on its certificate of analysis (COA) page, and researchers should cross-reference the COA tied to the specific lot listed on the CJC-1295 + Ipamorelin product page before beginning experimental work, alongside the broader quality testing overview describing the analytical standards applied across the catalog.
HPLC and MS Are Complementary, Not Redundant
As with any research peptide, HPLC quantifies purity but cannot on its own confirm molecular identity, while MS confirms identity but does not, run alone, quantify what proportion of a sample consists of impurities sharing a similar mass. A rigorous COA reports both for each compound in a CJC-1295 + Ipamorelin product. For a deeper technical treatment of how these two methods complement one another, see the HPLC vs. mass spectrometry peptide testing comparison.
| Documentation Element | What It Confirms | Why It Matters for This Combination |
|---|---|---|
| Separate HPLC traces | Purity of each compound independently | A blended figure can mask one compound’s impurity profile |
| Separate MS results | Correct molecular identity for each compound | Confirms neither compound has been substituted or misidentified |
| Lot-specific COA | Traceability to the specific vial received | Avoids relying on generic, non-lot-specific documentation |
Sourcing Considerations: Evaluating a Research Peptide Supplier
The reliability of any CJC-1295 Ipamorelin research program depends directly on the quality of the material used to generate it. This section outlines what a research buyer should evaluate before selecting a supplier, independent of price.
Documentation Transparency
A supplier serious about supporting legitimate GH-axis research should make lot-specific COAs readily accessible for combination products like CJC-1295 + Ipamorelin, with both compounds documented independently as described in the previous section. Vague or generic purity claims not tied to a specific lot are a signal to look elsewhere.
Testing Methodology and Independence
Beyond simply publishing a COA, it matters who performed the testing and by what method. In-house HPLC/MS testing is a reasonable baseline, but third-party verification adds an additional layer of confidence by removing any incentive conflict between the entity synthesizing the peptides and the entity certifying their purity. Researchers building a long-term sourcing relationship should ask directly whether COAs reflect in-house testing, third-party testing, or both, and should review a supplier’s general quality testing practices before committing to a source.
Packaging, Labeling, and Cold-Chain Handling
Because both CJC-1295 and Ipamorelin are lyophilized peptides sensitive to temperature and moisture exposure, appropriate packaging — light-protected, properly sealed vials — and shipping practices that avoid unnecessary thermal excursions in transit are meaningful quality indicators, not cosmetic packaging concerns. Labeling should clearly indicate lot number, research-use-only status, and the specific form of CJC-1295 supplied (with or without DAC), given the functional distinction covered earlier in this guide.
Research-Use-Only Framing as a Compliance Signal
A supplier’s marketing and labeling language is itself a quality indicator. Suppliers that frame products strictly around research applications, avoid therapeutic or outcome-based claims, and clearly state research-use-only status are more likely to be operating within a compliance framework appropriate for this category, reducing the risk of relying on a supplier whose broader claims are not grounded in verifiable science.
Supplier Evaluation Checklist
| Evaluation Criterion | What to Look For |
|---|---|
| Lot-specific COA availability | Published or easily requestable, with both compounds documented independently |
| Testing methodology disclosed | HPLC + MS at minimum; ideally third-party verified |
| DAC status disclosed for CJC-1295 | Product documentation specifies with-DAC or without-DAC form |
| Labeling accuracy | Research-use-only stated clearly; no therapeutic claims |
| Storage/shipping practices | Appropriate packaging; minimal thermal excursion risk |
Red Flags Worth Naming Directly
- No lot-specific documentation, or documentation reused across multiple listed batches.
- No disclosure of whether the CJC-1295 component includes DAC or not.
- Marketing language describing outcomes, results, or effects rather than research applications.
- Pricing dramatically below category norms with no corresponding testing documentation.
These red flags carry real consequences for combination products specifically, since two compounds’ worth of synthesis and quality risk are bundled into a single vial.
Storage, Stability, and Reconstitution for Laboratory Use
Proper storage and reconstitution practice is where well-sourced, well-documented CJC-1295 and Ipamorelin either retain their integrity through an experimental protocol or degrade in ways that quietly undermine data quality.
Storage of Lyophilized Material
Prior to reconstitution, lyophilized CJC-1295 and Ipamorelin should be stored in accordance with the supplier’s labeled recommendations — typically frozen, protected from light, and kept sealed to minimize moisture exposure. Lyophilized peptides are generally more stable in the freeze-dried state than in solution, which is why research-grade peptides are supplied lyophilized rather than pre-dissolved. Vials should be allowed to reach room temperature before opening to minimize condensation inside the vial.
Reconstitution Practice
Reconstitution refers to dissolving lyophilized peptide in an appropriate diluent to prepare a stock solution for laboratory use. Common considerations include:
- Diluent selection — bacteriostatic water is commonly used in peptide research settings because its preservative content helps limit microbial growth in a solution used across multiple laboratory sessions; sterile water without preservative may be preferred for certain single-use assay preparations. See certificate of analysis documentation for lot-specific handling notes, and consult general reconstitution guidance before beginning.
- Gentle mixing technique — diluent should be added slowly along the vial wall rather than directly onto the lyophilized cake, with gentle swirling rather than shaking, since vigorous agitation can promote peptide aggregation or denaturation at the air-liquid interface.
- Visual inspection post-reconstitution — a properly reconstituted solution should appear clear without visible particulate matter; cloudiness suggests a reconstitution or stability problem that should be investigated before use in any assay.
- Independent handling of each compound — where CJC-1295 and Ipamorelin are supplied as separate vials rather than a pre-blended product, each should be reconstituted according to its own specific chemistry, since their differing molecular size and structure can affect optimal reconstitution technique.
Post-Reconstitution Storage and Stability
Once reconstituted, both peptide solutions are considerably less stable than the lyophilized form and should generally be stored refrigerated and used within the timeframe indicated by supplier stability data or the research team’s own stability characterization. Researchers should also be attentive to potential adsorption to plastic labware surfaces, which can subtly reduce effective concentration in a stock solution over time if not accounted for in experimental design — this consideration applies to both compounds, though the effect can differ given their differing size and hydrophobicity.
Stability Differences Between the Two Compounds
Because CJC-1295 (particularly the DAC-conjugated form) and Ipamorelin differ substantially in molecular size and chemistry, they should not automatically be assumed to share identical stability profiles once reconstituted. Researchers running combined-compound protocols over extended timeframes should characterize or confirm stability for each compound independently, rather than applying a single stability assumption across both.
| Handling Stage | Best Practice | Risk If Skipped |
|---|---|---|
| Pre-reconstitution storage | Freezer, light-protected, sealed | Moisture ingress, premature degradation |
| Reconstitution technique | Slow diluent addition, gentle swirl, per-compound approach | Aggregation, denaturation |
| Post-reconstitution storage | Refrigerated, used within supplier-indicated window | Loss of activity, unreliable assay data |
| Stability characterization | Assessed independently for CJC-1295 and Ipamorelin | Assuming shared stability profile that does not hold in practice |
Laboratory Handling and Safety Practices
Because CJC-1295 and Ipamorelin are supplied strictly for in-vitro laboratory and research use, handling practices should follow standard laboratory biosafety and chemical-handling protocols applicable to peptide research generally.
Personal Protective Equipment
Standard laboratory PPE — gloves, eye protection, and a lab coat — should be worn when handling lyophilized peptide material and when preparing reconstituted solutions, consistent with an institution’s standard operating procedures for bioactive compound handling. Because lyophilized peptide powder can become airborne during handling, particularly when opening vials, work should be conducted in a manner that minimizes aerosolization, such as within a fume hood or biosafety cabinet where institutional protocols call for it.
Spill and Waste Handling
Spilled lyophilized material or reconstituted solution should be handled according to institutional chemical waste protocols. Because these research peptides are bioactive at the receptor level in the systems under study, they should not be treated as biologically inert for disposal purposes — institutional environmental health and safety guidance should govern disposal of both waste solution and any contaminated consumables.
Labeling and Chain-of-Custody Practices
Reconstituted stock solutions and working dilutions should be clearly labeled with compound identity (including CJC-1295 DAC status where relevant), concentration, reconstitution date, and preparer initials at minimum. This is especially important in a multi-user laboratory environment where several GH-axis compounds may be stored in close proximity, since mislabeling risk increases with the number of structurally related compounds a laboratory keeps on hand simultaneously.
Research-Use-Only Scope Boundaries
All handling, storage, and experimental use of CJC-1295 and Ipamorelin sourced through Royal Peptide Labs should remain within the bounds of in-vitro laboratory and research applications. This guide does not provide, and should not be interpreted as providing, guidance for any application outside that scope. Laboratory personnel and institutional oversight bodies should be consulted regarding any institution-specific requirements beyond the general practices summarized here.
Documentation for Reproducibility
Thorough documentation of handling conditions — reconstitution date, diluent used, storage temperature history, and freeze-thaw count for any reconstituted aliquots — supports reproducibility and allows a research team to retrospectively evaluate whether an unexpected result might be attributable to compound handling rather than to the biological system under study.
- Record reconstitution date and diluent lot alongside each compound’s own lot number.
- Track freeze-thaw cycles separately for CJC-1295 and Ipamorelin aliquots.
- Note storage temperature excursions if a freezer or refrigerator event is logged during the compounds’ storage window.
- Retain each lot’s COA alongside experimental records for that lot, not filed separately where it may become disconnected from the data it supports.
Common Research Questions and Experimental Design Considerations
Beyond the mechanistic and sourcing questions already covered, research teams working with CJC-1295 and Ipamorelin frequently encounter a set of recurring practical and experimental-design questions. This section addresses the most common of them directly.
How Should a Naive Research Team Begin Characterizing a New Lot?
Before layering any experimental question on top of newly received material, a baseline characterization step is advisable: confirm the COA’s HPLC and MS data for both CJC-1295 and Ipamorelin against the specific lot in hand, perform a visual and solubility check upon reconstitution, and, where feasible, run a basic receptor-signaling assay against a known reference standard for each compound to confirm the lot behaves pharmacologically as expected before committing it to a larger study.
Should CJC-1295 and Ipamorelin Always Be Studied Together?
Not necessarily. While combined-compound protocols are common and mechanistically well-motivated, many valid research questions call for studying each compound in isolation — for example, characterizing GHRH-receptor-specific signaling kinetics independent of any GHS-R1a input. Researchers should let the specific hypothesis, not convention, determine whether a combined or single-compound design is appropriate.
What Reference Compounds Make Sense for Comparative Work?
As discussed in the comparison section above, appropriate reference compounds depend on the research question. A study isolating GHRH-receptor-specific behavior should compare CJC-1295 against Sermorelin or Tesamorelin, not against a GHRP-class compound. A study isolating GHS-R1a-specific behavior should compare Ipamorelin against GHRP-6, GHRP-2, or Hexarelin, not against a GHRH-class compound. Cross-class comparisons (GHRH-class versus GHRP-class) are appropriate only when the research question specifically concerns convergent pathway behavior, as in combined-compound protocols.
How Does DAC Status Affect Comparative Interpretation?
As covered earlier, failing to specify or confirm whether a CJC-1295 sample includes the DAC modification is a common source of apparent inconsistency between studies or protocols. Any comparative literature review or internal replication effort should explicitly confirm DAC status for every CJC-1295 reference before drawing conclusions about discrepant findings.
What Are Common Sources of Variability Between Labs?
Cross-laboratory variability in GH-axis secretagogue research is frequently attributable to differences in somatotroph or receptor expression level between nominally similar cell lines maintained in different laboratories, differences in passage number, differences in reconstitution and handling practice, and differences in assay readout technology. None of these are unique to CJC-1295 or Ipamorelin, but a combined-compound protocol compounds the number of places such variability can enter a study.
How Should Unexpected Results Be Interpreted?
An unexpected or null result in a CJC-1295- or Ipamorelin-focused assay should prompt review of compound handling, DAC status confirmation, and lot documentation before being interpreted as a genuine biological finding. Confirming COA data against the specific lot, checking reconstitution and storage history, and, where practical, re-testing with a freshly reconstituted aliquot are reasonable first steps.
How Should Combined-Compound Ratios Be Approached in Study Design?
When CJC-1295 and Ipamorelin are studied together, researchers must decide how to set the relative concentration of each compound within a combined-exposure protocol. Because the two compounds act through structurally distinct receptors with different binding affinities and different downstream signaling amplification characteristics, there is no inherent reason to assume that equal molar concentrations of each compound will produce a “balanced” contribution from each pathway. A methodologically sound approach is to first characterize each compound’s individual concentration-response relationship in the chosen model system, and to use that data to inform a combined-exposure matrix design — rather than defaulting to an arbitrary fixed ratio carried over from an unrelated protocol or from general industry convention.
| Question | Design Consideration |
|---|---|
| Should the study use combined or single-compound exposure? | Driven by the specific hypothesis — convergent-pathway questions need combined design; isolated-pathway questions do not |
| Which CJC-1295 form should be used? | With-DAC for extended-exposure designs; without-DAC (Mod GRF 1-29) for acute/short-window designs |
| How to isolate GHS-R1a-specific contribution? | Use Ipamorelin against non-GHRP comparators, or against less-selective GHRPs to highlight selectivity differences |
| How to reduce lot-to-lot variability in longitudinal studies? | Source multiple study aliquots from the same verified lot where the study timeline allows |
Documentation, Compliance, and the 2026 Research Landscape
Every claim, product listing, and piece of guidance in this CJC-1295 Ipamorelin research guide operates within a research-use-only (RUO) framework, and that framework shapes both how these compounds should be documented internally and how the broader research field around them continues to develop.
What “Research-Use-Only” Means in Practice
A research-use-only designation indicates that a compound is supplied and intended strictly for laboratory and in-vitro research applications — not for any diagnostic, therapeutic, or other application outside a controlled research setting. This designation reflects the actual state of the compound’s characterization and shapes every downstream decision about how it should be labeled, marketed, and discussed.
Institutional Documentation Practices
Laboratories incorporating CJC-1295 and Ipamorelin into an active research program should maintain internal documentation consistent with institutional standard practices for bioactive research compounds, including procurement records tied to lot-specific COAs, storage and handling logs, and, where applicable, institutional biosafety or research compliance review appropriate to the laboratory’s governing framework.
Growing Interest in Dual-Pathway GH-Axis Research
The general trajectory of GH-axis secretagogue research has increasingly moved toward multi-pathway investigation — protocols that examine GHRH-receptor and GHS-R1a signaling together rather than in isolation — reflecting a broader research hypothesis that GH regulation is best understood as an integrated, multi-input circuit rather than a collection of independent pathways. CJC-1295 and Ipamorelin’s pairing sits squarely within this trend, and the comparative literature examining combined-agonist behavior against single-pathway controls continues to expand.
Methodological Advances Supporting This Research
Advances in assay technology — including higher-throughput signaling assays capable of distinguishing cAMP and calcium signaling within the same experimental run, improved ex-vivo tissue culture techniques, and more sophisticated animal-model phenotyping for pulsatile GH release — have made it increasingly feasible to characterize dual-pathway GH-axis pharmacology with a level of mechanistic detail that would have been impractical with earlier assay technology.
Staying Current as a Research Buyer
Given how actively this research area continues to move, laboratories sourcing CJC-1295 and Ipamorelin for ongoing programs are well served by periodically revisiting supplier documentation (COAs are lot-specific and should be reviewed with each new lot), periodically re-running the PubMed and ClinicalTrials.gov searches referenced at the end of this guide, and maintaining relationships with suppliers who demonstrate ongoing investment in testing rigor. Royal Peptide Labs’ broader growth hormone peptides research category is a reasonable starting point for tracking adjacent GHRH- and GHRP-class compounds as the field continues to develop, alongside related tissue-repair and metabolic research lines such as the retatrutide research guide, the KLOW peptide blend guide, the Wolverine Stack peptide guide, and the MOTS-c research guide for researchers building out a broader multi-pathway research program.
Cross-Referencing Findings Across the GH-Axis Literature
Because CJC-1295 and Ipamorelin sit within a larger family of GHRH- and GHRP-class research compounds, findings reported for one compound in this family are sometimes informally extrapolated to another based on shared receptor class alone. This is a methodologically risky habit. A finding reported for Sermorelin at the GHRH receptor, for instance, should not be assumed to apply directly to CJC-1295 without accounting for the stabilizing substitutions and, where relevant, DAC conjugation that distinguish the two compounds structurally. Likewise, a finding reported for GHRP-6 at GHS-R1a should not be assumed to apply to Ipamorelin without accounting for the selectivity differences documented earlier in this guide. Rigorous literature review in this space means tracking findings at the level of the specific compound tested, not merely the receptor class it happens to engage — which is precisely why this guide repeatedly directs readers to the searchable, compound-specific literature rather than to generalized receptor-class summaries.
Frequently Asked Questions
What is CJC-1295, in simple pharmacological terms?
CJC-1295 is a synthetic peptide characterized in the research literature as an analog of growth-hormone-releasing hormone (GHRH), engineered with amino acid substitutions that improve resistance to enzymatic degradation relative to native GHRH fragments. It is studied as an agonist at the GHRH receptor on pituitary somatotrophs and is supplied strictly for laboratory research use.
What is Ipamorelin, in simple pharmacological terms?
Ipamorelin is a synthetic pentapeptide classified as a growth hormone-releasing peptide (GHRP), studied as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by the endogenous hormone ghrelin. It is characterized in the literature as more receptor-selective than several earlier GHRP-class compounds.
Why are CJC-1295 and Ipamorelin studied together rather than separately?
Because they act on two distinct receptor systems — the GHRH receptor and GHS-R1a — that converge on the same pituitary somatotroph cell through different intracellular signaling pathways. Researchers study them together to investigate how these two convergent inputs interact at the level of GH-axis signaling, a question that cannot be answered by studying either compound alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes an additional chemical modification (a Drug Affinity Complex) designed to promote covalent binding to circulating serum albumin, which is reported to extend the compound’s functional presence in biological systems. CJC-1295 without DAC — sometimes labeled Mod GRF 1-29 — lacks this conjugate and is generally studied for shorter-window signaling protocols.
How does Ipamorelin differ from earlier GHRPs like GHRP-6?
Ipamorelin is reported in the literature to be more selective for GHS-R1a, with comparatively limited cross-reactivity at receptor pathways linked to cortisol, ACTH, and prolactin secretion, relative to earlier GHRP-class compounds such as GHRP-6, which are associated with more pronounced activity at those adjacent pathways.
What does ‘research-use-only’ mean for these compounds?
Research-use-only designates a compound as supplied strictly for laboratory, in-vitro, and preclinical research applications — not for diagnostic, therapeutic, or any application outside a controlled research setting. Suppliers and researchers alike are expected to frame all use and communication accordingly.
How should CJC-1295 and Ipamorelin be stored before reconstitution?
Lyophilized CJC-1295 and Ipamorelin should generally be kept frozen, protected from light, and sealed against moisture exposure, consistent with the specific storage guidance provided on their certificate of analysis and product labeling. Vials should be allowed to reach room temperature before opening to reduce condensation risk.
How can a laboratory verify the purity of a CJC-1295 + Ipamorelin product?
Purity and identity should be verified using a lot-specific certificate of analysis that documents HPLC purity data and mass spectrometry identity confirmation for each compound independently, since a single blended purity figure can obscure a problem isolated to one component of the product.
What model systems are used to study CJC-1295 and Ipamorelin’s receptor pharmacology?
Research spans dissociated pituitary cell culture for isolated receptor-signaling assays, ex-vivo pituitary explants for more physiologically relevant signaling context, hypothalamic-pituitary co-culture systems for capturing GHS-R1a’s dual-level effects, and animal models for systemic GH-pulsatility and IGF-1 feedback research.
Are CJC-1295 and Ipamorelin the same molecule across all suppliers?
Not necessarily in practice, even when labeled identically. Synthesis quality, purity, DAC status (for CJC-1295), and identity can vary meaningfully between suppliers and even between lots from the same supplier, which is why independent, lot-specific HPLC and mass spectrometry documentation is essential before any research use.
Scientific References
The following are live search links into PubMed and ClinicalTrials.gov, rather than citations to specific papers, so that researchers always land on the current, indexed literature rather than a static and potentially outdated reference list.
- CJC-1295 — PubMed search
- Ipamorelin — PubMed search
- Growth hormone releasing hormone receptor agonist — PubMed search
- Ghrelin receptor GHS-R1a growth hormone secretagogue — PubMed search
- CJC-1295 — ClinicalTrials.gov search
- Ipamorelin — ClinicalTrials.gov search
- Growth hormone pulsatile secretion somatostatin — PubMed search
- Peptide HPLC mass spectrometry purity analysis — PubMed search
All products and information from Royal Peptide Labs are intended strictly for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.